Sunovion's Latuda wins FDA nod for bipolar depression

07/2/2013 | Pharmaceutical Business Review Online

Sunovion Pharmaceuticals obtained the FDA's approval to market Latuda, or lurasidone, as a monotherapy and in combination with either lithium or valproate in adults with bipolar depression. The approval was based on favorable data from two double-blind studies.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC